Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …

For complex diseases, most drugs are highly ineffective, and the success rate of drug
discovery is in constant decline. While low quality, reproducibility issues, and translational …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …

Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …

A major rate-limiting step in developing more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …

Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …

Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …

The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …

The mesenchymal subtype of glioblastoma is thought to be determined by both cancer cell-
intrinsic alterations and extrinsic cellular interactions, but remains poorly understood. Here …